



Receipt

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Stewart D. Lyman et al.,

Attorney Docket No.: 2813-L

Serial No.: 08/994,468

Group Art Unit: 1615

Filed: December 19, 1997

Examiner: Unknown

For: MEDIUM CONTAINING FLT3 LIGAND FOR CULTURING  
HEMATOPOIETIC CELLS

**REQUEST TO CORRECT FILING RECEIPT**

Application Processing Division's Customer Correction Division  
Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir:

Applicants enclose a copy of the Official Filing Receipt that was received from the Patent and Trademark Office. The Filing Receipt contains incorrect information regarding the priority applications. The Continuing Data as claimed by applicants should read as follows:

"This application is a continuation of application Serial No. 08/444,627 filed May 19, 1995, which is a divisional of application Serial No. 08/243,545 filed May 11, 1994, now allowed and issued as U.S. Patent No. 5,554,512, which is a continuation-in-part of application Serial No. 08/209,502 filed March 7, 1994, now abandoned, which is a continuation-in-part of application Serial No. 08/162,407 filed December 3, 1993, now abandoned, which is a continuation-in-part of application Serial No. 08/111,758 filed August 25, 1993, which is a continuation-in-part of application Serial No. 08/106,463 filed August 12, 1993 which is a continuation-in-part of application Serial No. 08/068,394 filed May 24, 1993, now abandoned.

The invention title is incorrect on the Official Filing Receipt, with the misspelling of the word hematopoietic and should read as follows: "MEDIUM CONTAINING FLT3 LIGAND FOR CULTURING HEMATOPOIETIC CELLS."

Applicants therefore request the aforementioned corrections be made and a new Filing Receipt issued.

Respectfully submitted,



Stephen L. Malaska  
Attorney for Applicant  
Reg. No. 32,655

Immunex Corporation  
Law Department  
51 University Street  
Seattle, WA 98101  
Telephone: (206) 587-0430

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Application Processing Division's Customer Correction Division, Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date indicated below.

Date: October 2, 1998

Signed: Camilla C. Edwards  
Camilla C. Edwards

FILING RECEIPT



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
08/994,468	12/19/97	1615	\$1,200.00	2813-L	0	8	8

LAW DEPARTMENT  
IMMUNEX CORPORATION  
51 UNIVERSITY STREET  
SEATTLE WA 98101

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Application Processing Division's Customer Correction Branch within 10 days of receipt. Please provide a copy of the Filing Receipt with the changes noted thereon.

Applicant(s) STEWART D. LYMAN, SEATTLE, WA; M. PATRICIA BECKMANN,  
POULSBO, WA.

FOREIGN FILING LICENSE GRANTED 03/31/98

TITLE  
MEDIUM CONTAINING FLT3 LIGAND FOR CULTURING HEMATOPOIETIC CELLS

PRELIMINARY CLASS: 435

00000000000000000000000000000000